These results are consistent with clinical data showing that low LINC00261 expression is associated with more aggressive pancreatic cancer (PDAC) phenotypes and worse patient outcomes, underscoring its potential as both a biomarker and a therapeutic target in pancreatic adenocarcinoma (PDAC) [4]. The gene discussed is LINC00261; the disease is familial pancreatic carcinoma.